We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Department of Pharmaceutics, Holy Grace Academy of Pharmacy, Mala Thrissur, Kerala
Oral solid dosage forms (OSDFs), such as tablets, capsules, powders, and granules, continue to dominate pharmaceutical therapy because of their stability, affordability, ease of administration, and better patient acceptance. This review outlines the complete pharmaceutical product lifecycle associated with OSDFs, beginning from early drug discovery and extending to post-marketing surveillance and lifecycle management. The article discusses major aspects of formulation development, including preclinical and clinical studies, pilot-scale production, optimization strategies, and stability evaluation. It also explains the importance of scale-up, commercial manufacturing, Good Manufacturing Practices (GMP), validation procedures, and quality control systems in maintaining product consistency and regulatory compliance. In addition, the review summarizes regulatory pathways, Common Technical Document (CTD) requirements, approval procedures for new and generic products, and the regulatory framework followed in India. Commercial considerations such as packaging, labeling, product launch strategies, pricing, and market competition are also highlighted. Furthermore, the role of pharmacovigilance in monitoring product safety, patient-related risks, and long-term therapeutic performance is discussed. Overall, this review presents an integrated understanding of the scientific, manufacturing, regulatory, and commercial factors involved in the successful development and lifecycle management of oral solid dosage forms.
Oral solid dosage forms are among the most commonly used pharmaceutical preparations worldwide. Tablets, capsules, powders, and granules are generally preferred because they are easy to administer, economical, portable, and provide accurate dosing. Unlike liquid dosage forms, OSDFs deliver a fixed quantity of active pharmaceutical ingredient (API), minimizing dosing errors and improving patient compliance.
Another major advantage of oral solid dosage forms is their stability. APIs present in solid formulations are usually less susceptible to microbial contamination and chemical degradation compared to liquid or semisolid preparations. As a result, OSDFs often possess a longer shelf life and require fewer preservatives.
An oral solid dosage form is defined as a pharmaceutical formulation administered through the oral route in a solid state. After administration, the dosage form disintegrates or dissolves in the gastrointestinal tract, allowing the release and absorption of the active drug.
Modern pharmaceutical technologies have expanded the possibilities for OSDF development. Depending on therapeutic requirements, formulations may be designed for immediate release, delayed release, sustained release, buccal delivery, or intestinal targeting. In addition, oral solid dosage forms are considered highly suitable for industrial scale-up because established manufacturing techniques and regulatory pathways are already available.
TYPES OF ORAL SOLID DOSAGE FORMS
DRUG PRODUCT DEVELOPMENT
Drug development begins with the identification of a biological target associated with a disease condition. The target may include proteins, enzymes, receptors, nucleic acids, or metabolites that play a role in disease progression. Once the target is identified, researchers screen multiple chemical or biological compounds to determine which candidates interact effectively with it.
The identified compounds then undergo preliminary investigations to evaluate their pharmacological activity, toxicity profile, absorption characteristics, and possible adverse effects. During this stage, lead compounds are optimized to improve efficacy while reducing toxicity and undesirable effects. Only the most promising candidates proceed to further development.
Preclinical research is carried out before human exposure to determine whether a drug candidate is sufficiently safe for clinical trials. This stage involves both in vitro studies, which are performed using laboratory techniques and cell cultures, and in vivo studies conducted in animal models.
Researchers assess pharmacokinetic properties such as absorption, distribution, metabolism, and excretion, along with dose-response relationships and toxicological effects. All studies must comply with Good Laboratory Practices (GLP) to ensure reliability, consistency, and proper documentation of experimental data.
Successful completion of preclinical studies provides the evidence required to proceed to clinical testing in humans.
Clinical research involves the evaluation of the drug candidate in human subjects to establish safety, efficacy, dosage range, and long-term therapeutic performance. Clinical trials are generally divided into four phases.
Phase I studies involve a small number of healthy volunteers and mainly focus on safety evaluation, dose tolerance, and pharmacokinetics. Phase II trials are performed in patients to assess therapeutic efficacy and identify common side effects. Phase III studies involve a much larger patient population to confirm effectiveness and monitor adverse reactions under broader clinical conditions. After regulatory approval and marketing, Phase IV studies continue to monitor long-term safety and real-world effectiveness.
If the overall clinical evidence demonstrates that the drug is safe and effective, the product proceeds to regulatory review.
Following successful clinical development, pharmaceutical companies submit regulatory applications such as a New Drug Application (NDA) or Biologics License Application (BLA) to the appropriate regulatory authority.
Regulatory agencies review extensive data related to product quality, safety, efficacy, manufacturing processes, labeling, and overall benefit-risk balance. The evaluation process also includes inspection of manufacturing facilities and assessment of compliance with quality standards.
Approval is granted only when the regulatory authority is satisfied that the product consistently meets all required scientific and regulatory standards.
Even after approval, continuous monitoring of drug safety remains essential. Post-marketing surveillance helps identify rare adverse effects or long-term complications that may not have been observed during clinical trials.
Programs such as adverse drug reaction reporting systems, pharmacovigilance databases, and manufacturing inspections contribute to continuous safety evaluation. Regulatory authorities also monitor promotional activities, labeling updates, and manufacturing compliance to ensure continued product quality and patient safety.
Pilot batch manufacturing serves as an important transition stage between laboratory-scale formulation development and commercial production. A pilot batch is produced using equipment that resembles industrial manufacturing systems while remaining smaller than commercial-scale production.
The primary purpose of pilot-scale manufacturing is to evaluate whether the formulation can be successfully scaled up without affecting product quality, stability, or performance. Pilot batches also help generate data for process validation, equipment selection, optimization studies, and stability testing.
According to regulatory guidance, a pilot batch for oral solid dosage forms is generally considered to be at least 10% of the proposed commercial batch size or not less than 100,000 dosage units.
Optimization is a systematic approach used to refine formulation variables and manufacturing conditions to achieve consistent product quality. The objective is to ensure that critical quality attributes such as assay, dissolution, hardness, friability, and stability remain within predefined specifications.
Formulation optimization focuses on modifying the concentration and selection of excipients. For example, adjusting the amount of binder can improve tablet hardness, while increasing disintegrant concentration may enhance drug release.
Process optimization involves controlling manufacturing variables such as mixing time, granulation parameters, drying temperature, compression force, and coating conditions. Improper process settings may negatively affect compressibility, moisture content, dissolution, or overall stability.
Pilot-scale studies and optimization activities are closely interconnected. Data obtained during pilot production often reveal formulation or process-related issues that require correction before commercial manufacturing.
STABILITY STUDIES
Stability studies are systematic investigations designed to determine the shelf life and recommended storage conditions of pharmaceutical products. These studies evaluate the influence of environmental factors such as temperature, humidity, and light on product quality over time.
The primary objective of stability testing is to ensure that the product remains safe, effective, and within specification throughout its labeled expiry period.
According to ICH guidelines, stability studies are categorized into long-term, intermediate, and accelerated studies. Long-term studies are conducted under recommended storage conditions for extended periods, whereas accelerated studies expose products to elevated stress conditions to predict degradation patterns more rapidly.
For oral solid dosage forms, stability evaluation includes testing of appearance, assay, dissolution, hardness, friability, disintegration time, moisture content, and degradation products. These parameters help confirm that both chemical integrity and physical properties remain acceptable throughout storage.
Guidelines for Stability Studies:
MANUFACTURING AND QUALITY COMPLIANCE
Scale-up refers to the process of increasing production volume from laboratory or pilot scale to full commercial manufacturing while maintaining product quality, safety, and efficacy.
The major objective of scale-up is to ensure that the product developed during research can be manufactured consistently on a larger scale without introducing variability.
Scale-up generally progresses through laboratory-scale production, pilot-scale manufacturing, exhibit or registration batches, and finally commercial-scale manufacturing.
Several factors must be carefully controlled during scale-up, including raw material properties, equipment performance, environmental conditions, process parameters, and documentation practices. Equipment qualification and process validation are essential components of successful scale-up.
Commercial production represents the routine large-scale manufacturing of pharmaceutical products following successful development, validation, and regulatory approval.
Commercial manufacturing must comply with current Good Manufacturing Practices (cGMP). Production activities are performed according to approved Master Formula Records (MFRs), Batch Manufacturing Records (BMRs), and Standard Operating Procedures (SOPs).
Properly trained personnel, validated equipment, controlled environments, and effective quality systems are essential for maintaining batch-to-batch consistency and preventing contamination.
Continuous monitoring and regulatory compliance remain necessary throughout commercial manufacturing to ensure product quality and patient safety.
Good Manufacturing Practices (GMP) form the foundation of pharmaceutical quality assurance. GMP guidelines ensure that medicinal products are consistently manufactured and controlled according to established quality standards appropriate for their intended use.
For oral solid dosage forms, GMP compliance includes strict control over manufacturing processes, personnel training, equipment qualification, sanitation, environmental conditions, documentation, and quality assurance systems.
Tablet manufacturing requires validation of granulation processes to ensure uniform drug distribution. Compression parameters such as hardness, weight variation, thickness, and friability must be carefully controlled. Coating operations should provide uniform coverage and maintain stability. In-process tests such as disintegration and dissolution are routinely performed to ensure product quality.
Capsule manufacturing requires careful monitoring of shell quality, fill weight uniformity, and environmental conditions. Soft gelatin capsules also require sealing integrity tests and microbial control measures due to the biological origin of gelatin.
Manufacturing of powders and granules requires maintenance of blend uniformity, moisture control, and adequate flow properties. Packaging systems should protect products from moisture and contamination, while dust control systems help maintain both product quality and operator safety.
Modified-release formulations require strict validation of release mechanisms and dissolution profiles. Polymer quality, process reproducibility, and manufacturing consistency are critical for maintaining controlled drug release.
Process validation is the collection and evaluation of data demonstrating that a manufacturing process consistently produces products meeting predetermined quality standards.
Cleaning validation provides documented evidence that cleaning procedures consistently remove residues of APIs, excipients, cleaning agents, and microbial contaminants to acceptable limits.
Type A cleaning generally involves dismantling equipment and performing extensive cleaning procedures using Clean-Out-of-Place (COP) or Clean-In-Place (CIP) systems.
Type B cleaning is usually performed during batch-to-batch changeovers under similar manufacturing conditions.
Effective cleaning validation is essential for preventing cross-contamination and ensuring product safety.
Quality control plays a major role in ensuring the safety, efficacy, and consistency of pharmaceutical products. In oral solid dosage manufacturing, quality control systems operate throughout production and after completion of manufacturing.
In-Process Quality Control (IPQC):
IPQC involves monitoring production activities during stages such as blending, granulation, compression, and coating. The objective is to identify deviations early and prevent defects in the finished product.
Common IPQC tests include hardness testing, weight variation, friability, moisture content determination, and dissolution checks.
Finished Product Quality Control (FPQC):
FPQC is performed after completion of manufacturing to verify that the final product complies with established specifications.
Typical FPQC evaluations include assay, content uniformity, dissolution testing, disintegration time, impurity analysis, and appearance testing.
Together, IPQC and FPQC provide a comprehensive quality assurance system that supports regulatory compliance and patient safety.
Pharmaceutical regulation in India is governed primarily by the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. Regulatory responsibilities are shared between central and state authorities to ensure the safety, quality, and efficacy of pharmaceutical products.
CDSCO functions as the primary national regulatory authority responsible for approval of new drugs, inspection of manufacturing facilities, and post-marketing safety monitoring.
ICMR provides ethical guidelines for biomedical and clinical research involving human participants.
RCGM supervises biotechnology-based pharmaceutical products involving genetic engineering.
DBT regulates biotechnology-related pharmaceutical products and policy implementation.
IECs review and approve clinical trials at the institutional level to ensure ethical conduct and participant protection.
State authorities enforce drug laws and monitor pharmaceutical manufacturing and distribution activities.
A regulatory dossier is a structured collection of documents submitted to regulatory authorities to demonstrate the safety, efficacy, and quality of a pharmaceutical product.
For oral solid dosage forms, dossiers generally follow the Common Technical Document (CTD) format, which contains five modules covering administrative information, summaries, quality data, nonclinical studies, and clinical studies.
Approval procedures involve the regulatory evaluation of pharmaceutical products before market authorization.
The process generally includes preclinical studies, investigational applications, clinical trials, submission of NDA or ANDA dossiers, regulatory review, GMP inspections, marketing authorization, and post-marketing surveillance.
Each stage is designed to ensure that the final pharmaceutical product is safe, effective, and manufactured according to approved quality standards.
COMMERCIALIZATION AND POST-MARKETING
Successful commercialization of oral solid dosage forms requires integration of scientific, manufacturing, regulatory, and commercial planning.
Pre-launch activities involve formulation optimization, stability evaluation, process validation, and technology selection. Regulatory approval, supply chain planning, and commercial-scale manufacturing are also critical.
Market access strategies include physician engagement, promotional campaigns, patient support programs, and post-launch performance monitoring.
Packaging and Labeling Requirements
Packaging materials for oral solid dosage forms must protect the product from moisture, oxygen, light, and physical damage.
Blister packs and HDPE bottles are commonly used packaging systems. Labels must include essential information such as product name, strength, batch number, expiry date, storage conditions, and directions for use.
Tamper-evident packaging and serialization systems improve product safety and traceability.
Pricing and Market Competition
Pricing of oral solid dosage forms is influenced by manufacturing costs, patent protection, competition, therapeutic value, and market demand.
Generic manufacturers usually compete through cost-based pricing, while innovator products often follow value-based pricing models.
Companies also attempt product differentiation through modified-release systems, orally disintegrating tablets, and other formulation innovations.
Pharmacovigilance involves continuous monitoring of the safety and effectiveness of pharmaceutical products after marketing approval.
For oral solid dosage forms, pharmacovigilance extends beyond monitoring drug-related adverse effects and also includes risks associated with formulation design, swallowing difficulties, dose dumping, and improper administration.
Monitoring systems help identify issues related to product quality, patient compliance, bioavailability changes, and manufacturing consistency.
Regulatory authorities use tools such as Periodic Safety Update Reports (PSURs), post-approval inspections, and adverse event reporting systems to ensure continued product safety.
Lifecycle management refers to strategies used to maximize the therapeutic, commercial, and regulatory value of pharmaceutical products throughout their market life.
Pharmaceutical companies use lifecycle management approaches to improve patient convenience, extend market exclusivity, optimize manufacturing processes, and maintain competitiveness.
Examples of lifecycle management strategies for oral solid dosage forms include development of controlled-release formulations, fixed-dose combinations, orally disintegrating tablets, advanced coating systems, and line extensions with new strengths or dosage forms.
These approaches help pharmaceutical products remain relevant in changing therapeutic and commercial environments.
CONCLUSION
The lifecycle of oral solid dosage forms involves a multidisciplinary process that extends from early drug discovery to post-marketing surveillance and lifecycle management. Each stage, including formulation development, stability testing, scale-up, commercial manufacturing, validation, quality control, regulatory approval, and pharmacovigilance, plays an essential role in ensuring product quality, safety, and therapeutic effectiveness.
Oral solid dosage forms continue to remain the most widely used pharmaceutical preparations because of their convenience, stability, affordability, and patient acceptability. Successful development and commercialization of these products require coordination between scientific research, manufacturing operations, regulatory systems, and commercial strategies.
Overall, effective lifecycle management ensures that safe, stable, high-quality, and therapeutically effective oral solid dosage forms are consistently delivered to patients while maintaining regulatory compliance and long-term market sustainability.
ACKNOWLEDGEMENT
We express our sincere gratitude to Almighty God for His grace and blessings, without which this work would not have been possible.
We would like to sincerely thank the teachers and faculty members of our college especially the Department of Pharmaceutics for their guidance, encouragement, and support throughout the preparation of this review article. We also extend our heartfelt thanks to our dear friends and fellow students for their cooperation, helpful discussions, and constant motivation during this work. Finally, we are grateful to our institution for providing the facilities and academic environment necessary for completing this article successfully. Above all, we express our deepest gratitude to our parents and family members for their unconditional love, prayers, and constant support.
We would also like to acknowledge everyone who directly or indirectly contributed to the completion of this work. Their support and encouragement played an important role in the successful preparation of this review article. We extend our sincere thanks to all.
REFERENCES
K. R. Veena, S. Bindhilathy, K. K. Sana Fathima, C. T. Fida Fathima, P. J. Hijas Muhammed, An Overview of Pharmaceutical Product Lifecycle of An Oral Solid Dosage Form, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 5864-5874. https://doi.org/10.5281/zenodo.20343505
10.5281/zenodo.20343505